SCHEMBL20210

SCHEMBL20210

C=S(=O)(Cl)c1ccc(Cl)nc1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 1/20 0.51
ALDH1A1 P00352 8/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 2/20 0.45
PKM P14618 2/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.43
EGFR P00533 2/20 0.41
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17509 0.83 SMN1; SMN2 (0.56) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL29483829 0.83 SMN1; SMN2 (0.56) SMN1; SMN2MAPTALDH1A1POLBMEN1
Hydrochloric Acid SCHEMBL4803286 0.81 SMN1; SMN2 (0.55) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL23904091 0.79 SMN1; SMN2 (0.53) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL4804914 0.77 SMN1; SMN2 (0.59) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL4804922 0.77 KDM4E (0.59) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL2633979 0.77 KDM4E (0.59) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL188710 0.77 ALDH1A1 (0.63) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL19055 0.77 SMN1; SMN2 (0.55) SMN1; SMN2MAPTALDH1A1POLBMEN1
SCHEMBL29977958 0.77 SMN1; SMN2 (0.59) SMN1; SMN2MAPTALDH1A1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed